Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker RARE · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Tumor-induced Osteomalacia Disease Monitoring Program NCT04783428 · Tumor-induced Osteomalacia (TIO) No intervention | RARE Ultragenyx Pharmaceutical Inc | — | Active, not recruiting | 23 | Feb 28, 2032 | Registry ↗ |
| Nov 3, 2026 | A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Synd… NCT07157254 · Angelman Syndrome No intervention, GTX-102 | RARE Ultragenyx Pharmaceutical Inc | Phase 2 | Terminated was active, not recruiting | 55 | Oct 30, 2026 | Registry ↗ |
| Nov 3, 2026 | Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) NCT06617429 · Angelman Syndrome GTX-102, Sham-LP | RARE Ultragenyx Pharmaceutical Inc | Phase 3 | Terminated was active, not recruiting | 129 | Jul 10, 2026 | Registry ↗ |
| Nov 3, 2026 | Long-term Extension of GTX-102 in Angelman Syndrome NCT06415344 · Angelman Syndrome GTX-102 | RARE Ultragenyx Pharmaceutical Inc | Phase 3 | Terminated was active, not recruiting | 66 | Oct 30, 2026 | Registry ↗ |
| Oct 20, 2026 | Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta NCT05768854 · Osteogenesis Imperfecta Bisphosphonate, Setrusumab | RARE Ultragenyx Pharmaceutical Inc | Phase 3 | Active, not recruiting | 69 | Oct 23, 2025 | Registry ↗ |
| Oct 20, 2026 | Setrusumab vs Placebo for Osteogenesis Imperfecta NCT05125809 · Osteogenesis Imperfecta Setrusumab, Placebo | RARE Ultragenyx Pharmaceutical Inc | Phase 2/3 | Active, not recruiting | 183 | Oct 20, 2025 | Registry ↗ |
| Oct 14, 2026 | Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program NCT06636383 · Glycogen Storage Disease Type Ia No Intervention | RARE Ultragenyx Pharmaceutical Inc | — | Recruiting | 140 | Dec 2036 | Registry ↗ |
| Oct 14, 2026 | A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Pat… NCT05139316 · Glycogen Storage Disease Type IA DTX401, Placebo | RARE Ultragenyx Pharmaceutical Inc | Phase 3 | Completed | 52 | Feb 20, 2024 | Registry ↗ |
| Oct 13, 2026 | First-in-human Study of UX016 in GNEM NCT07511556 · GNE Myopathy UX016, Placebo | RARE Ultragenyx Pharmaceutical Inc | Phase 1/2 | Recruiting | 24 | Dec 2028 | Registry ↗ |
| Oct 2, 2026 | MPS IIIA Disease Monitoring Program NCT07855562 · MPS IIIA, Sanfilippo Syndrome No Intervention | RARE Ultragenyx Pharmaceutical Inc | — | Not yet recruiting | 55 | Oct 2038 | Registry ↗ |
| Sep 28, 2026 | Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta NCT06636071 · Osteogenesis Imperfecta setrusumab | RARE Ultragenyx Pharmaceutical Inc | Phase 3 | Active, not recruiting | 6 | Jan 2027 | Registry ↗ |
| Sep 25, 2026 | A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease NCT04884815 · Wilson Disease UX701, Standard of Care (SOC) | RARE Ultragenyx Pharmaceutical Inc | Phase 1/2 | Active, not recruiting | 82 | Mar 2029 | Registry ↗ |
| Sep 22, 2026 | Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH NCT02716246 · MPS IIIA, Sanfilippo Syndrome UX111, Prophylactic Immunomodulatory (IM) Therapy | RARE Ultragenyx Pharmaceutical Inc | Phase 2/3 | Recruiting | 36 | Mar 2029 | Registry ↗ |
| Sep 17, 2026 | A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric P… NCT05933200 · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Triheptanoin, MCT Oil | RARE Ultragenyx Pharmaceutical Inc | Phase 3 | Active, not recruiting | 69 | Aug 2027 | Registry ↗ |
| Sep 9, 2026 | Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency NCT05345171 · OTC Deficiency DTX301, Placebo | RARE Ultragenyx Pharmaceutical Inc | Phase 3 | Active, not recruiting | 37 | Sep 2027 | Registry ↗ |
| Aug 28, 2026 | X-linked Hypophosphatemia Disease Monitoring Program NCT03651505 · X-linked Hypophosphatemia, Hypophosphatemic Rickets No intervention | RARE Ultragenyx Pharmaceutical Inc | — | Active, not recruiting | 782 | Dec 2032 | Registry ↗ |
| Aug 27, 2026 | Mucopolysaccharidosis VII Disease Monitoring Program NCT03604835 · Mucopolysaccharidosis VII, MPS VII No Intervention | RARE Ultragenyx Pharmaceutical Inc | — | Recruiting | 50 | Apr 2032 | Registry ↗ |
| Jul 31, 2026 | Expanded Access to Triheptanoin NCT03773770 · Long Chain Fatty Acid Oxidation Disorders Triheptanoin | RARE Ultragenyx Pharmaceutical Inc | — | Available | — | — | Registry ↗ |
| Jul 30, 2026 | Expanded Access to Mepsevii NCT03775174 · MPS VII, Mucopolysaccharidosis VII Mepsevii | RARE Ultragenyx Pharmaceutical Inc | — | Available | — | — | Registry ↗ |
| Jul 17, 2026 | Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA NCT04360265 · Mucopolysaccharidosis IIIA, MPS IIIA No Investigational Product, Adjuvant Immunomodulatory (IM)… | RARE Ultragenyx Pharmaceutical Inc | Phase 3 | Enrolling by invitation | 41 | Aug 2027 | Registry ↗ |
| Jun 3, 2026 | Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program NCT04632953 · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) No Intervention | RARE Ultragenyx Pharmaceutical Inc | — | Active, not recruiting | 150 | Dec 2035 | Registry ↗ |
| Jun 1, 2026 | Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency NCT03636438 · Ornithine Transcarbamylase (OTC) Deficiency No Intervention | RARE Ultragenyx Pharmaceutical Inc | — | Active, not recruiting | 11 | Dec 2029 | Registry ↗ |
| Mar 18, 2026 | Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia NCT03970278 · Glycogen Storage Disease Type IA, Von Gierke's Disease (GSD… No intervention | RARE Ultragenyx Pharmaceutical Inc | — | Completed | 12 | Feb 25, 2025 | Registry ↗ |
| Jan 9, 2026 | A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome NCT04259281 · Angelman Syndrome GTX-102 | RARE Ultragenyx Pharmaceutical Inc | Phase 1/2 | Completed | 74 | Jan 8, 2025 | Registry ↗ |
| Jul 23, 2025 | Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta NCT05312697 · Osteogenesis Imperfecta Setrusumab | RARE Ultragenyx Pharmaceutical Inc | Phase 2 | Terminated | 2 | Jul 7, 2022 | Registry ↗ |
| May 29, 2024 | Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa NCT04708015 · Glycogen Storage Disease Type IA No Intervention | RARE Ultragenyx Pharmaceutical Inc | — | Completed | 15 | Mar 4, 2022 | Registry ↗ |
| Apr 16, 2024 | Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type… NCT04990388 · Glycogen Storage Disease Type III UX053, Placebo | RARE Ultragenyx Pharmaceutical Inc | Phase 1/2 | Terminated | 9 | Mar 20, 2023 | Registry ↗ |
| Sep 28, 2023 | Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants… NCT05196165 · Glycogen Storage Disease Type III No Intervention | RARE Ultragenyx Pharmaceutical Inc | — | Terminated | 14 | Mar 2, 2023 | Registry ↗ |
| Aug 1, 2023 | Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolle… NCT02214160 · Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency… UX007 | RARE Ultragenyx Pharmaceutical Inc | Phase 2 | Completed | 94 | Dec 3, 2020 | Registry ↗ |
| Jul 25, 2023 | Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease NCT04088734 · MPS IIIA, Sanfilippo Syndrome ABO-102 | RARE Ultragenyx Pharmaceutical Inc | Phase 1/2 | Terminated | 5 | Mar 10, 2022 | Registry ↗ |
| Jul 5, 2023 | A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 NCT03118570 · Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Ty… setrusumab, Calcium | RARE Ultragenyx Pharmaceutical Inc | Phase 2 | Completed | 112 | Oct 1, 2019 | Registry ↗ |
| Jul 3, 2023 | An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Impe… NCT03216486 · Osteogenesis Imperfecta BPS804 | RARE Ultragenyx Pharmaceutical Inc | Phase 2 | Withdrawn | 0 | Nov 1, 2018 | Registry ↗ |
| Jun 12, 2023 | Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease NCT04909346 · Ornithine Transcarbamylase Deficiency, Wilson Disease | RARE Ultragenyx Pharmaceutical Inc | — | Terminated | 51 | Nov 17, 2022 | Registry ↗ |
| Mar 24, 2023 | Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in… NCT02736188 · Hereditary Inclusion Body Myopathy, Distal Myopathy With Ri… Aceneuramic Acid Extended-Release Tablets | RARE Ultragenyx Pharmaceutical Inc | Phase 3 | Terminated | 143 | Jan 10, 2018 | Registry ↗ |
| Jan 26, 2023 | Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbam… NCT02991144 · Ornithine Transcarbamylase (OTC) Deficiency scAAV8OTC, Reactive Corticosteroid Taper Regimen | RARE Ultragenyx Pharmaceutical Inc | Phase 1/2 | Completed | 16 | Dec 16, 2021 | Registry ↗ |
| Nov 18, 2022 | Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program NCT04812106 · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) No Intervention | RARE Ultragenyx Pharmaceutical Inc | — | Terminated | 8 | Oct 27, 2022 | Registry ↗ |
| Nov 18, 2022 | Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia… NCT03517085 · GSD1 DTX401, steroid regimen | RARE Ultragenyx Pharmaceutical Inc | Phase 1/2 | Completed | 12 | Nov 2, 2021 | Registry ↗ |
| Nov 14, 2022 | Observational Study of Males With Creatine Transporter Deficiency NCT02931682 · Creatine Deficiency, X-linked | RARE Ultragenyx Pharmaceutical Inc | — | Terminated | 50 | Oct 24, 2022 | Registry ↗ |
| Sep 16, 2022 | Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Ad… NCT01406977 · Hypophosphatasia BPS804 | RARE Ultragenyx Pharmaceutical Inc | Phase 2 | Completed | 8 | Sep 2012 | Registry ↗ |
| Sep 15, 2022 | Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mi… NCT01406548 · Osteopenia, Osteoporosis BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804 | RARE Ultragenyx Pharmaceutical Inc | Phase 2 | Completed | 44 | Oct 2013 | Registry ↗ |
| Sep 14, 2022 | Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease NCT01806610 · Chronic-kidney Disease Stage 5D on Stable Hemodialysis BPS804, Placebo | RARE Ultragenyx Pharmaceutical Inc | Phase 2 | Withdrawn | 0 | Apr 2014 | Registry ↗ |
| Sep 13, 2022 | Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disea… NCT04574830 · Glycogen Storage Disease Type III No Intervention | RARE Ultragenyx Pharmaceutical Inc | — | Completed | 18 | Jun 30, 2022 | Registry ↗ |
| Apr 29, 2022 | Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease NCT04531189 · Wilson Disease | RARE Ultragenyx Pharmaceutical Inc | — | Completed | 16 | Mar 25, 2022 | Registry ↗ |
| Feb 18, 2022 | Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficie… NCT04717453 · Ornithine Transcarbamylase Deficiency No Intervention | RARE Ultragenyx Pharmaceutical Inc | — | Terminated | 1 | Dec 15, 2021 | Registry ↗ |
| Jan 6, 2022 | Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe… NCT02971969 · Hemophilia B | RARE Ultragenyx Pharmaceutical Inc | — | Completed | 6 | Nov 6, 2021 | Registry ↗ |
| May 11, 2021 | Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta NCT01417091 · Osteogenesis Imperfecta BPS804 | RARE Ultragenyx Pharmaceutical Inc | Phase 2 | Completed | 10 | Dec 2012 | Registry ↗ |
| Feb 11, 2021 | A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-… NCT01886378 · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), Carnit… UX007 | RARE Ultragenyx Pharmaceutical Inc | Phase 2 | Completed | 29 | Aug 25, 2016 | Registry ↗ |
| Aug 28, 2020 | Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorde… NCT03768817 · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) No Intervention | RARE Ultragenyx Pharmaceutical Inc | — | Completed | 20 | Jun 8, 2020 | Registry ↗ |
| Jul 30, 2020 | A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subject… NCT02432144 · Sly Syndrome, MPS VII UX003 | RARE Ultragenyx Pharmaceutical Inc | Phase 3 | Completed | 12 | Jan 14, 2019 | Registry ↗ |
| Jul 30, 2020 | A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in… NCT02230566 · MPS 7, Sly Syndrome UX003, Placebo | RARE Ultragenyx Pharmaceutical Inc | Phase 3 | Completed | 12 | May 2016 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:05 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances